Even prior to approval, new data from cabozantinib and combination PD-L1 and CTLA-4 inhibition are transforming treatment of metastatic RCC.
This interactive treatment decision aid will let you compare your choice of therapy for patients with advanced RCC with expert recommendations from Bernard Escudier, MD; Bradley A. McGregor, MD; James M. G. Larkin, MD, PhD; Michael Staehler, MD, PhD; and Cora N. Sternberg, MD, FACP.
Bradley A. McGregor, MD, reviews and summarizes country- and patient-specific treatment recommendations from an international panel of experts based on recent practice-changing clinical trial results in RCC.
In this downloadable slideset, Bradley A. McGregor, MD, discusses the optimal treatment approaches and management options for patients with advanced RCC from an international perspective.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.